Staphylococcal enterotoxin B (SEB), produced by the gram-positive bacterium Staphylococcus aureus, is responsible for food poisoning and toxic shock syndrome, and is considered a potential bioterrorism agent. Unfortunately, still now no approved vaccines are available against SEB. In this study, we constructed a series of nontoxic SEB mutants (mSEBs) and examined whether these mSEBs provide protective immunity against SEB challenge. These mSEB vaccine candidates did not demonstrate superantigen activity in mouse splenocyte cultures. Immunization with the vaccine candidates triggered the production of IgG-antibodies with neutralizing activity. In addition, increased production of IgG1 and IgG3 was observed after immunization, which signifies both Th1-and Th2-induced immune responses. Among the vaccine candidates tested, S9, a double mutant (N23A and Y90A) and S19, a quadruple mutant (N23A, Y90A, R110A, and F177A), demonstrated complete protection against a lethal SEB challenge. Altogether, our results strongly suggest that these mSEBs could be an effective recombinant SEB vaccine candidates for further/future preclinical and clinical studies.
Introduction
Staphylococcus aureus is a highly versatile pathogen that causes a wide range of human diseases, including food poisoning, pneumonia, osteomyelitis, septicemia, and toxic shock. The bacterial toxins play a significant role in its pathogenicity. Staphylococcal enterotoxin B (SEB) is one of the most common exotoxins (Proft and Fraser, 2007; Krakauer and Stiles, 2013) , which enters the body through ingestion and inhalation. It has been previously reported that, when food contaminated with SEB is ingested, the exotoxin results in vomiting, abdominal cramps, followed by diarrhea (Le Loir et al., 2003) . Likewise, toxin exposure that occurs through inhalation causes a sudden onset of fever, cough, and myalgia, leading to respiratory distress. Subsequently, when the toxin is released into the circulatory system, an increase in vascular inflammation results in life-threatening toxic shock syndrome (Ahanotu et al., 2006) . The amount of SEB required to induce disease symptoms is as low as 4 ng/kg, and a dose of 20 ng/kg could be lethal (Gill, 1982; Burnett et al., 2005) . Since low doses of SEB are sufficient to cause toxicity, SEB is considered a potential biological weapon. Furthermore, SEB is resistant to environmental stresses such as heat, proteolytic degradation, and changes in pH, making it a particularly attractive agent for biowarfare or bioterrorism (Mantis, 2005) . Thus, based on the classification by the Center for Disease Control (CDC), SEB is classified as a category-B agent (Mantis, 2005; Ahanotu et al., 2006) . SEB is a single chain-protein of approximately 28 kDa, comprising 240 amino acids that form two distinct, compact domains: domain I (30e120 amino acids) and domain II (127e239 amino acids). Domain I consists of a bebarrel and three helices, and contains some hydrophobic residues. Domain II is composed of antiparallel b-sheets packed against a central a-helix. This compact, three-dimensional structure enables SEB to be highly resistant to protease cleavage (Papageorgiou et al., 1998) . Unlike conventional antigens, which are processed into small peptides, SEB binds directly to major histocompatibility class II (MHC II) molecules on the antigen presenting cell surface. The SEB-MHC ll complex is then bound to the Vb chain of a T cell receptor (TCR), forming a trimolecular complex. As a consequence of the cross-linking of SEB, MHC ll, and TCR, T cells release a variety of cytokines, such as Interferon-g (IFN-g), Interleukin-2, and TNF-a, causing a cytokine storm that can lead to toxic shock syndrome (Fraser and Proft, 2008; Pinchuk et al., 2010) . Since SEB can bind to MHC II without prior processing, and has the ability to stimulate up to 30% of lymphocytes, SEB is considered a superantigen.
Previously, SEB vaccine studies focused on the use of a toxoid vaccine that was made by extended incubation in formalin. While a formalin-treated SEB toxoid vaccine has demonstrated some degree of protection efficiency in animal models, it has not been approved for use in humans (Mantis, 2005) . A fuller understanding of the three-dimensional structure of the SEB/MHC ll/TCR complex now enables a more promising alternative for SEB vaccine development. Mutagenesis of critical residues involved in the TCR and MHC ll receptor binding portions of SEB has become a central effort for new vaccine development. Several residues, including F44, L45, Y89, and N23, are critical for the interaction of SEB with MHC ll molecules and TCR (Woody et al., 1997; Ulrich et al., 1998) . The nontoxic recombinant forms of SEB have been investigated for their ability to elicit protective immune responses (Stiles et al., 2001; Coffman et al., 2002; Boles et al., 2003) . Recently, this SEB vaccine, named STEBVax, has completed Phase 1 clinical trials. It is an SEB molecule containing triple mutations (L45R, Y89A, and Y94A), which induces the generation of antibodies that are protective against SEB-induced diseases (Hudson et al., 2013; Chen et al., 2016) .
For this report, we studied the potential of SEB mutants (mSEBs) as novel vaccine candidates, and constructed a series of molecules lacking superantigenic activity. We characterized the immune response against these novel vaccine candidates using a mouse model, and assessed their protective effects against a lethal challenge by wild type SEB.
Material and methods

Design of vaccine candidates
We downloaded the PDB (Protein Data Bank) file (ID: 4C56) from the RCSB (Research Collaboratory for Structural Bioinformatics) Protein Data Bank and corrected its incomplete structure using Discovery Studio's clean protein software (DS version 3.5, BIOVIA). The amino acids on SEB which are involved in the binding with MHC or TCR were defined by structural modeling. The non-toxic vaccine candidate was designed through the alanine substitution of the confirmed amino acids. Finally, the mutated candidates were selected following homology modeling.
Generation of mutated SEB gene
The nucleotide sequence encoding SEB in Staphylococcus aureus strain 14458 was obtained from GenBank (accession no. M11118). Site-specific mutagenesis reactions were performed to produce four SEB vaccine candidates based on their structural properties. S2 (F44A, E67A) differed from the wild type toxin at residues 44 (phenylalanine changed to alanine) and 67 (glutamic acid changed to alanine). The other vaccine candidates, such as S9 (N23A, Y90A), S19 (N23A, Y90A, R110A, F177A), and S26 (F44A, E67A, Y90A, R110A, F177A) were also mutated in a similar manner. The fulllength of each of the mutated SEB genes was chemically synthesized (Bioneer, Daejeon, Korea), and the gene was cloned into a pET28a vector (Novagen, Cambridge, USA).
Expression and purification of SEB proteins
The plasmid pET-28a encoding mSEBs or wild type SEB were individually transformed into E. coli BL21 (DE3) cells. The transformants were selected from Luria-Bertani (LB)/kanamycin plates and inoculated into 5 mL of LB broth-kanamycin medium. The cells were grown at 37 C overnight and subcultured in 2 L of LB 0.6 ± 0.1. After 3 h of induction, cells were harvested by centrifugation at 4000 rpm for 20 min and resuspended in lysis buffer containing 50 mM NaH 2 PO 4 , 300 mM NaCl, and 10 mM imidazole (pH 8.0). Complete cell lysis was achieved by sonication, and the lysate was treated with 5 mg/mL DNase I. Cell debris was pelleted by centrifugation at 10,000 rpm for 30 min. The supernatants were filtered through MF™ membrane 0.45 mm filters (Millipore, Massachusetts, USA) and applied to an Ni-NTA resin column (Qiagen, Hilden, Germany) for 1 h at 4 C. The column was washed with filtered water, 1 N NaOH, 20%ethanol, and deionized water. Flowthrough fractions were collected from the affinity column and washed with washing buffer containing 50 mM NaH 2 PO 4 , 300 mM NaCl, and 20 mM imidazole (pH 8.0). The resin-bound proteins were eluted by adding elution buffer containing increasing concentrations of imidazole (30e250 mM). Elution fractions containing mSEB proteins were analyzed by 12% SDS-PAGE. We also prepared the control antigen (rSEB) with the same sequence as STEBVax, a recombinant SEB vaccine, as described previously (Coffman et al., 2002) .
Western blot analysis
Six-week-old female BALB/c mice were used to produce polyclonal antibody. Mice were immunized intraperitoneally with 100 mg of rSEB in PBS (pH 7.4) mixed with Freund's Complete Adjuvant (FCA) at week 0, and then 100 mg of rSEB in PBS mixed with Freund's Incomplete Adjuvant (FIA) at week 1 and 2. The serum samples were collected at week 3 and used as polyclonal antibody for Western blot analysis. Wild type SEB and mSEBs were first separated by 12% SDS-PAGE and transferred to a nitrocellulose membrane by electroblotting. The membrane was blocked with 6% skim milk, and then washed with TBS buffer containing 0.1% Tween-20. After washing, the membrane was incubated with a mouse anti-rSEB polyclonal antibody at a 1:5000 dilution for 1 h at 25 C. Membranes were then washed and treated with the secondary antibody, goat anti-mouse IgG-HRP (Santa Cruz Biotechnology, Santa Cruz, USA), at a 1:5000 dilution for 1 h at 25 C. After additional washing, the bound antibody was detected using Western Lightening™Plus-ECL (PerkinElmer, Waltham, USA).
Superantigen activity of mSEB
To investigate the capability of mSEB to function as a superantigen, mouse spleen cells were suspended in RPMI 1640 medium supplemented with 10% fetal calf serum. Spleen cells (1 Â 10 6 /well) were incubated with various concentrations of wild type SEB or mSEB in 24-well plates at 37 C for 72 h. Mouse Interferon-g (IFN-g) production was quantified using a Mouse IFN-gamma ELISA Kit (R&D Systems, Minneapolis, USA).
Immunization and antibody detection
Six-week-old female BALB/c mice (n ¼ 5e6/group) were immunized with the vaccine candidates. For vaccination, each mSEB was dissolved in PBS and emulsified 1:1 in Alhydrogel adjuvant 2% (Invivogen, San Diego, USA). Mice were injected with 100 mL of the emulsion, which contained 10 or 20 mg of the mSEB protein, intramuscularly, thrice, at 2-week intervals. The doses in this study were selected based on previous studies of STEBVax (Coffman et al., 2002; Boles et al., 2003) . Control group mice received only the adjuvant. Sera were collected every two weeks by retro-orbital bleeding and stored at À20 C until assaying. Concurrently, the mice were weighed at one-week intervals.
Anti-SEB antibody in sera was measured by indirect ELISA. Microplates were coated with each recombinant mSEB protein (0.5 mg/mL) in PBS and incubated for 1 h at 37 C. Plates were then washed with washing buffer and blocked with PBS buffer containing 1% BSA. Serum samples diluted in blocking buffer were added to the plates, incubated for 1 h at 37 C, and then washed four times with washing buffer. The goat anti-mouse antibody IgG-HRP (Santa Cruz Biotechnology) was diluted in blocking buffer at a 1:2000 ratio, added to each well, and incubated for 30 min. Following washing, plates were treated with TMB substrate (3,3 0 ,5,5 0 -tetramethylbenzidine) solution for 30 min in the dark at 25 C. The reaction was stopped by adding 1 N H 2 SO 4 and reaction products were measured at OD 450 . The endpoint of titration was determined as described previously (Kim et al., 2015) .
Neutralization assay
For determination of the neutralizing activities of anti-mSEB sera against IFN-g secretion induced by wild type SEB, anti-mSEB sera (1:50 dilutions) were pre-incubated with wild type SEB Fig. 3 . Superantigen activity of mSEBs in mouse splenocytes. Mouse spleen cells were isolated and cultured in the presence of various concentrations wild type SEB and mSEBs. After 72 h of culture, supernatants were collected and IFN-g secretion was evaluated by ELISA. Levels of IFN-g that were below the 30 pg/mL detection limit for this ELISA were designated nondetectable (ND). Values represent the mean ± standard deviation.
(0.5 mg/mL) for 1 h at 37 C before addition to mouse splenocyte cultures. After 72 h of incubation at 37 C in a humidified 5% CO 2 incubator, the cell culture supernatants were collected, and IFN-g secretion was assessed using a Mouse IFN-gamma ELISA Kit (R&D Systems).
Analysis for IgG isotype by ELISA
Antibody isotypes were analyzed using an Isotyping Kits for Immunoglobulins (eBioscience, San Diego, USA) following the manufacturer's guidelines. Serum samples were obtained eight weeks after primary injection, and diluted in TBS buffer (25 mM Tris, 1.15 M NaCl, pH 7.2) at 1:2000. Plates were viewed at 450 nm wavelength in a Microplate Spectrophotometer (Molecular Devices, Sunnyvale, USA) ELISA plate reader.
Challenge test
One week after final immunization, mice (n ¼ 6/group) were challenged intraperitoneally with 2 mg (approximately 10 LD 50 ) of wild type SEB, and 4 h later with 5 mg of LPS, as described previously (Leclaire et al., 1996; Boles et al., 2003) . Untreated mice (control groups) received wild type SEB plus adjuvant only. The mice were observed for 11 days after challenge, to determine the status of vaccine protection. All animal tests were conducted following protocols approved by the Institutional Animal Care and Use Committees (IACUC) of the Agency of Defense Development, where the animal experiments were conducted (approval ID: 1513).
Statistical analysis
Data were expressed as the mean and standard error of the mean. Student's t-test was used to determine the significance of the differences between the control and experimental groups. P < 0.05 was considered statistically significant.
Results
Expression of mSEB
By analyzing the SEB complex with MHC and TCR, it was confirmed that the F44 and E67 amino acids are interacting with MHC, and N23, Y90, R110, and F177 amino acids are interacting with TCR (Fig. 1) . Also, previous reports suggest that several residues of SEB, including F44, E67, and N23 are important for binding MHC II and TCR (Neil et al., 1996; Woody et al., 1997; Ulrich et al., 1998) . Based on these results, we performed sets of site-directed mutagenesis to generate mSEBs: double mutant F44A/E67A (named S2) and N23A/Y90A (S9), quadruple mutant N23A/Y90A/ R110A/F177A (S19), and quintuple mutant F44A/E67A/Y90A/R110A/ F177A (S26). In addition, according to the homology modeling, there were no differences in structure between the wild type SEB and the selected vaccine candidates (Fig. 2) . The pET-28a plasmid, encoding the mutated SEB gene, was transferred into E. coli BL21 (DE3) cells. The recombinant mSEB proteins were His-tagged at N-termini and purified by using Ni-NTA column. His-tag removed recombinant mSEB was analyzed by SDS-PAGE, and each recombinant mSEBs was observed as a single band of the expected size for recombinant SEB (28 kDa) (Supplementary data 1A) . The immunological reactivity of the mSEBs with polyclonal anti-rSEB antibody was assayed by western blotting. As depicted in western blotting result (Supplementary data 1B) , the antibodies are readily bound to each of the purified mSEBs, suggesting that mSEBs share common epitopes with rSEB.
Superantigen activity of mSEB
Next, to ensure that any mSEB causing superantigenic activity would be eliminated as a vaccine candidate, we evaluated cytokine production induced by mSEBs in the mouse spleen cells. Our result shows that no detectable IFN-g secretion resulted from treatment with vaccine candidates S9, 19, and S26, using doses as high as 1 mg/ mL of the mSEB (Fig. 3) . In contrast, considerable IFN-g secretion was detected after treating with vaccine candidate S2, with a dose as low as 0.25 mg/mL.Therefore, we eliminated S2 from our vaccine candidates list for our further experiments. All these results confirm that S9, S19, and S26 mSEBs have no toxic effect when we used as vaccine candidates.
Antibody production in mSEB vaccinated mice
To analyze the immune responses induced by vaccine candidates, BALB/c mice (n ¼ 5e6/group) were immunized intramuscularly with mSEB. Mice were injected with 10 mg or 20 mg of mSEB in Alhydrogel adjuvant, thrice, at 2-week intervals. ELISA was performed to determine the presence of anti-mSEB IgG antibodies in serum samples collected 1 week after each immunization. As indicated in Fig. 4A , active IgG antibody production was detected in serum samples collected from mice immunized with 10 mg of Fig. 7 . Protection of BALB/c mice vaccinated with mSEBs. Mice (n ¼ 6/group) were immunized with 20 mg of mSEB vaccine via intramuscular injection, followed by two boosters of the same dose at 2-week intervals. Mice were challenged intraperitoneally with wild type SEB (10 LD 50 ) one week after the final immunization. Control group mice were challenged but were immunized with Alhydrogel adjuvant only. mSEBs. No significant differences was observed between the production of IgG antibodies after 10 mg and 20 mg injection doses (data not shown). In contrast, no antibody production was detected in mice injected only with an adjuvant. High antibody titers were found in mice injected with S9 and S19 vaccine candidates 5 weeks after initial immunization. These titers are comparable to those from the use of the rSEB (Fig. 4B) . A similar level of total IgG production continued on week 8 following initial immunization. To determine the safety of our vaccine candidates, we also monitored changes in the body weights of the mice during the vaccination period. As shown in Fig. 4C , there was no difference in body weights between vaccinated and control mice. Overall, these results indicate that our vaccine candidates induce strong mSEB-specific antibody responses and are safe as a toxin-based vaccine.
Neutralization activities of anti-mSEB antibodies
Since substantial levels of mSEB-specific antibodies were obtained from the serum samples of mSEB-vaccinated mice, we next performed in vitro neutralization assays. Neutralization assays were used to evaluate if serum samples from vaccinated mice could prevent wild type SEB-stimulated IFN-g secretion in mouse splenocytes that were treated with 0.5 mg/mL wild type SEB. Fig. 5 shows that diluted serum samples (1:50 dilutions) from S9 and S19 vaccinated mice effectively inhibited SEB-induced IFN-g secretion in vitro compared to control animals, and we also observed the same result in the case of rSEB (data not shown). However, S26 candidate was not as effective as S9 and S19. These results clearly indicate that antibodies induced by S9 and S19 are able to neutralize wild type SEB toxicity by nullifying cytokine production.
Antibody isotypes elicited by mSEB
To study the antigen-specific immune responses resulting from immunization with the mSEBs, both Th1-and Th2-mediated immune responses were analyzed in mSEB-immunized mice. The IgG isotype distribution was used as an indicator of mSEB elicited immune response type. A dramatic increase in IgG1 levels was observed in serum samples from vaccinated mice (Fig. 6) . The production of IgG3 was also considerably high in the vaccinated group compared to the control group (pre-immunized group), indicating that both humoral and cellular immune responses were induced by immunization with the mSEBs.
Protective effect immunization with mSEB
Next, the protective efficacy of mSEBs was explored in the experimental model of BALB/c mice challenged with SEB toxicity. BALB/c mice (n ¼ 6) were immunized by intramuscular injections of 20 mg of rSEB and mSEB plus adjuvant three times with 2-week intervals between injections. One week after the last booster immunization, the mice were challenged with 4 mg of wild type SEB (corresponding to 10 LD 50 ) by intraperitoneal injection. Control mice were injected with adjuvant alone. As shown in Fig. 7 , all mice vaccinated with rSEB, S9 or S19 exhibited complete protection from the toxin challenge. However, only 20% of S26 vaccinated mice survived. As expected, all control group mice died within 24 h after toxin challenge. These results indicate that the S9 and S19 vaccine candidates may provide efficient protection against lethal SEB challenge.
Discussion
Staphylococcus aureus causes serious infections in humans and can infect people of all ages; however, it is most severe in pediatric, geriatric, and immunocompromised patients (Klevens et al., 2007) . The incidence of S. aureus infections in underdeveloped countries is highest in infants up to one year of age, with mortality rates up to 50%. In the United Stated, illness from S. aureus infection contributes to approximately 300,000 hospitalizations per year (Nickerson et al., 2009) . S. aureus produces SEB, which causes disease and is regarded a superantigen due to its massive induction of T cell activation, leading to life-threatening toxic shock syndrome (Pinchuk et al., 2010 ). In addition, major concerns regarding SEB arise from its potential use as a bioterrorism agent. SEB was developed as an offensive biological weapon by the United States and the Soviet Union in the 1960s (Burnett et al., 2005) . Therefore, it is imperative to develop therapies and prophylactic vaccines for human use with complete protection against SEB.
Structural information regarding the interaction of SEB with MHC II molecules has been resolved by the crystal structure of the SEB-MHC II complex. Two main regions of SEB are involved in the binding of MHC II: a polar binding pocket derived from the b-barrel domain, and a hydrophobic reverse turn. The polar binding pocket contains residues E67, Y89, and Y115, whereas the hydrophobic reverse turn includes residues G43, F44, and L45 (Papageorgiou et al., 1998; Woody et al., 1998; Li et al., 1999) . The threedimensional structure of the SEB-TCR complex demonstrates that residues in both the large (L20, E22, N23, F177, and E210) and small (N60, Y90, and Y91) domains of SEB directly bind the TCR Vb chain (Li et al., 1999; Papageorgiou and Acharya, 2000) .
Several lines of research indicate that Staphylococcal enterotoxin superantigen activities can be nullified by rational and efficient site-directed mutagenesis and that genetically modified enterotoxins can be used as toxin-based vaccines (Stiles et al., 2001; Krupka et al., 2002; Hu et al., 2005) . Recent studies demonstrate that these toxin-based vaccines may protect against enterotoxin superantigen activity of the Staphylococcal enterotoxins A, B, and C, presumably by antibody-mediated neutralization (Hu et al., 2009; Inskeep et al., 2010) .
In the present study, single amino acid substitutions at positions, 23, 44, 67, 90, 110 , and 177 of SEB were created by sitedirected mutagenesis. Alanine was used as the replacement residue because it imposes minimal disruption to the original protein structure and does not yield electrostatic or steric effects (Lefevre et al., 1997) . F44 and E67 directly interact with the DR1 molecule of MHC II through hydrogen bond and salt bridges, respectively. In contrast, N23, Y90, R110, and F177 are involved in SEB-TCR interactions (Papageorgiou et al., 1998; Li et al., 1998) . Accordingly, we generated a set of non-toxic mSEBs as vaccine candidates, which included double, quadruple, and quintuple mutants. We also generated rSEB with the same sequence as STEBVax, which is a recombinant SEB vaccine under clinical trials, as a control (Coffman et al., 2002; Chen et al., 2016) .
First, we performed extensive studies to confirm that the mSEBs used in these studies lack the toxic effects of the staphylococcal superantigen, thus qualifying the mSEBs for further study as vaccine candidates. Of the mSEBs we tested by in vitro cytokine release assays, only three mSEBs (S9, S19, and S26) showed no trace of superantigenicity. It has been suggested that the superantigen mediates uncontrolled release of pro-inflammatory cytokines like IFN-g and TNF-a (Pinchuk et al., 2010; Krakauer and Stiles, 2013) . Spleen cell cultures are commonly used to study in vitro activation of cytokine release by superantigens (Inskeep et al., 2010) . Unlike the other three mSEBs we tested, treatment of spleen cells with S2 resulted in a detectable amount of IFN-g secretion. S2 contains a mutation of residues 44 and 67, which are on the N-terminal domain of SEB and have contact with the DR1 molecule of MHC II. It seems that while disruption of these residues may lead to less favorable binding of SEB to MHC II, the S2 still retains low T cell stimulating activity. Results from our in vivo experiments further mitigate safety concerns regarding mSEB use, as no weight loss was observed in mice vaccinated with S9, S19, or S26 mSEBs for the duration of the immunization experiments.
Next, we explored mSEB immunogenic potential using a mouse model. Our results demonstrate that high-titers of antibodies were induced with as little as two injections. Five weeks after immunization, S9, S19, S26, and rSEB induced high levels of IgG titers (>4.0 log titers), which remained elevated for the 8-week duration of the study. However, the highest titers were observed from S9 immunization, followed by S19 and S26. While the S9 and S19 mSEBs each induced a prominent antibody response, S26 resulted in a noticeably lower antibody titer in comparison. One possible explanation for this phenomenon is that the higher number of amino acid substitutions in S26, a quintuple mutant, may have disturbed the original structure of its epitopes, thereby weakening its immunogenicity. Additionally, the potency of mSEB-specific antibodies in neutralizing superantigen activities was assessed using cytokine release assays. Robust neutralizing antibodies responses were evident in the serum samples from S9 and S19 mSEBimmunized mice compared to samples from the pre-immunized mice. This indicates that antibodies against the S9 and S19 are able to neutralize superantigen activities and maybe protective against the lethal effects of wild type SEB. Our results are consistent with that of a previous study demonstrating that inhibition of inflammatory cytokine production is involved in the protective effects of a toxoid-based the Staphylococcal enterotoxins C vaccine (Hu et al., 2005) . It is well known that IgG2a, IgG2b, and IgG3 are associated with a Th1-like response, while the Th2 response is associated with induction of IgG1 in mice (Germann et al., 1995) . Interestingly, the serum samples from mSEB-immunized mice had significantly higher levels of IgG1 and IgG3 compared to samples from pre-immunized mice (P < 0.05). These results suggest that mSEB can induce both humoral and cellular immune responses. Clearly, an immune profile with a broad IgG isotype distribution is desirable for a SEB vaccine.
Finally, mice vaccinated with the mSEBs were challenged intraperitoneally with 10 LD 50 of wild type SEB. Same as the control antigen rSEB, both S9 and S19 were 100% protective against SEB toxicity in the mice, while S26 produced a partial protective effect. It seems that there is a correlation between antibody titers, neutralization activity and protective effects, which is consistent with results from a previous study. Boles et al. showed that direct correlation between serum titers and protection in primates (Boles et al., 2003) . Therefore, our results indicated that antibody titers and in vitro neutralization activity may be used a proxy indicator for protective efficacy of toxin-based SEB vaccine. Additionally, the effect of vaccination route on immune responses was considered. A previous report showed that administration of mutated SEB via subcutaneous injection was able to provide protection from S. aureus infection (Nilsson et al., 1999) . But our results demonstrate that there was no significant difference in vaccine efficacy between the intramuscular versus subcutaneous injection of the mSEBs (data not shown). Future studies will focus on determining doses and evaluating protective efficacy in animals, including non-human primates, for an accurate assessment.
At present, STEBVax is the only vaccine in the development process against SEB. With the exception of studies on STEBVax, there is very little research pertaining to SEB vaccine development. According to the presented study, we introduce new vaccine candidates against SEB, which are able to induce robust immunogenicity including full protection, neutralization of superantigen activity, and the potential to elicit both humoral and cellular immune responses. Our results broaden the perspectives for future initiatives in SEB vaccine development.
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